Overview

Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

Status:
Terminated

Trial end date:
2021-01-20

Target enrollment:

Participant gender:

Summary

This is a double-blind, randomized-withdrawal, placebo-controlled study in kidney transplant patients with AMR to evaluate the efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care (IVIG).

Phase:

Phase 3

Details

Lead Sponsor:

CSL Behring

Treatments:

Antibodies
Complement C1 Inactivator Proteins
Complement C1 Inhibitor Protein
Complement C1s
Immunoglobulins